Durvalumab and Tremelimumab

DRUG8 trials

Conditions

Adenocarcinoma of the BladderColorectal CancerHCCImmunotherapyMetastatic Adult Soft Tissue SarcomaMetastatic Bladder CancerNon-Transitional Cell Carcinoma of the Urothelial TractPlatinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Phase 1

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

WithdrawnNCT03802747

University of Colorado, DenverColorectal Cancer

Start: 2019-08-31End: 2024-12-31Updated: 2024-12-09

Phase 2

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

CompletedNCT02937818

AstraZenecaPlatinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Start: 2016-11-28End: 2023-11-27Updated: 2024-06-07

Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma

CompletedNCT03317457

AIO-Studien-gGmbHMetastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma

Start: 2017-12-15End: 2022-08-12Updated: 2023-06-15

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruitingNCT03385655

Canadian Cancer Trials GroupProstate Cancer

Start: 2018-08-01End: 2025-12-31Updated: 2025-08-21

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

CompletedNCT03430895

Memorial Sloan Kettering Cancer CenterAdenocarcinoma of the Bladder, Metastatic Bladder Cancer, Non-Transitional Cell Carcinoma of the Urothelial Tract +2

Start: 2018-01-31End: 2021-02-10Updated: 2021-12-01

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

CompletedNCT03911557

John L. Villano, MD, PhDTumor, Solid

Start: 2019-06-08End: 2025-10-10Updated: 2025-11-12

Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma

NCT04221555

Asan Medical CenterResectable Gastric or Gastroesophageal Junction Adenocarcinoma

Start: 2020-05-13End: 2025-04-30Target: 68Updated: 2023-12-29

Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment

Not yet recruitingNCT07168668

Chang Gung Memorial HospitalHCC, Immunotherapy, Tace

Start: 2025-09-15End: 2028-05-30Target: 90Updated: 2025-09-11

Journal of Clinical Oncology2025-05-282 citations

Canadian Cancer Trials Group (CCTG) IND.234/223: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)–A molecularly selected cooperative group platform study.

Journal of Clinical Oncology2025-05-28

Substudy C of the Canadian cancer trials group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A phase II study of darolutamide (DARO) selected by androgen-receptor (AR) circulating tumor DNA (ctDNA) in patients (PTS) with metastatic castration-resistant prostate cancer (mCRPC) after prior AR pathway inhibitors (ARPIs).

Journal of Clinical Oncology2025-05-28

Substudy F of the Canadian Cancer Trials Group (CCTG) IND.234: PC_BETS (Prostate Cancer Biomarker Enrichment and Treatment Selection)—A biomarker-selected phase II study of durvalumab and tremelilumab (DT) in patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC) resistant to AR pathway inhibitors (ARPI).

Journal of Clinical Oncology2025-05-28

Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

Clinical Cancer Research2024-07-177 citations

Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).

Journal of Clinical Oncology2024-06-01

Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.

Journal of Clinical Oncology2023-02-205 citations

Abstract CT533: Durvalumab (D) plus tremelimumab (T) in platinum-refractory/resistant extensive-stage small cell lung cancer (ES-SCLC): Efficacy, safety and ctDNA dynamics from Arm A of the phase 2 BALTIC study

Cancer Research2022-06-15

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.

2020-06-2623 citations

Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2020-05-2012 citations

CASPIAN: OS results from a randomised Phase III study of first-line Durvalumab ± Tremelimumab plus chemotherapy in ED-SCLC: OS-Ergebnisse von CASPIAN, einer randomisierten Phase-III-Studie zur Erstlinientherapie von Durvalumab ± Tremelimumab + Chemotherapie beim Extensive Stage kleinzelligen Lungenkarzinom (ES-SCLC)

Pneumologie2020-02-28

A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract.

Journal of Clinical Oncology2020-02-193 citations

Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

British Journal of Cancer2019-07-1466 citations

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study

Annals of Oncology2018-10-0137 citations

A phase II, open-label, multi-arm study of novel combinations of immunotherapies or DDR inhibitors in platinum-refractory, extensive disease small-cell lung cancer (ED-SCLC): BALTIC.

Journal of Clinical Oncology2017-05-208 citations

Durvalumab and Tremelimumab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers